BioNTech SE ADR (NASDAQ:BNTX)’s traded shares stood at 0.66 million during the last session, with the company’s beta value hitting 0.24. At the close of trading, the stock’s price was $122.68, to imply an increase of 2.40% or $2.88 in intraday trading. The BNTX share’s 52-week high remains $131.49, putting it -7.18% down since that peak but still an impressive 37.62% since price per share fell to its 52-week low of $76.53. The company has a valuation of $29.16B, with an average of 0.95 million shares in intraday trading volume over the past 10 days and average of 956.23K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for BioNTech SE ADR (BNTX), translating to a mean rating of 1.79. Of 13 analyst(s) looking at the stock, 2 analyst(s) give BNTX a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 9 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.59.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioNTech SE ADR (NASDAQ:BNTX) trade information
After registering a 2.40% upside in the last session, BioNTech SE ADR (BNTX) has traded red over the past five days. The 5-day price performance for the stock is 3.77%, and 36.08% over 30 days. With these gigs, the year-to-date price performance is 16.24%. Short interest in BioNTech SE ADR (NASDAQ:BNTX) saw shorts transact 2.68 million shares and set a 2.47 days time to cover.
The extremes give us $81 and $359 for target low and target high price respectively. As such, BNTX has been trading -192.63% off suggested target high and 33.97% from its likely low.
BioNTech SE ADR (BNTX) estimates and forecasts
Looking at statistics comparing BioNTech SE ADR share performance against respective industry, we note that the company has underperformed competitors. BioNTech SE ADR (BNTX) shares are 35.53% up over the last 6 months, with its year-to-date growth rate lower than industry average at -172.77% against 17.60%. Revenue is forecast to shrink -317.80% this quarter before jumping 48.80% for the next one. The rating firms project that company’s revenue will shrink -28.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is 732.22M. Meanwhile, for the current quarter, a total of 11 analyst(s) estimate revenue growth to 1.83B.
BNTX Dividends
BioNTech SE ADR has its next earnings report out on 2024-Nov-04. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is PRIMECAP MANAGEMENT CO/CA/ with 4.79 million shares, or about 1.9912% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $384.89 million.
